<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119613</url>
  </required_header>
  <id_info>
    <org_study_id>20010145</org_study_id>
    <nct_id>NCT00119613</nct_id>
  </id_info>
  <brief_title>A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether increasing or maintaining hemoglobin&#xD;
      concentrations with darbepoetin alfa, when administered with platinum-containing chemotherapy&#xD;
      in subjects with previously untreated extensive-stage small cell lung cancer (SCLC),&#xD;
      increases survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin concentration from baseline to the end of the chemotherapy treatment period</measure>
    <time_frame>from baseline to the end of the chemotherapy treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival time</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FACT-fatigue subscale scores from baseline to the end of study treatment</measure>
    <time_frame>from baseline to the end of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (including serious and treatment related)</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory values, changes in vital signs and incidence of concomitant medications</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1 - darbepoetin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darbepoetin alfa 300 mcg QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Group 2 - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darbepoetin alfa</intervention_name>
    <description>darbepoetin alfa</description>
    <arm_group_label>Group 1 - darbepoetin alfa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically proven SCLC, extensive-stage&#xD;
&#xD;
          -  Planned to receive chemotherapy of carboplatin or cisplatin plus etoposide every 3&#xD;
             weeks for 6 cycles&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          -  Life expectancy greater than or equal to 3 months&#xD;
&#xD;
          -  Hemoglobin concentration greater than or equal to 9.0 g/dL and less than or equal to&#xD;
             13g/dL&#xD;
&#xD;
          -  Adequate renal, liver and hematopoietic function&#xD;
&#xD;
          -  Subjects must sign and date a written Institutional Review Board /Independent Ethics&#xD;
             Committee-approved Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known primary hematologic disorder which could cause anemia&#xD;
&#xD;
          -  Brain metastases that are either symptomatic or treated with medications&#xD;
&#xD;
          -  Unstable or uncontrolled disease/condition, related to or affecting cardiac function&#xD;
&#xD;
          -  Other known primary malignancy within the past 5 years with the exception of&#xD;
             curatively treated basal cell carcinoma, squamous cell carcinoma in situ cervical&#xD;
             carcinoma or surgically cured malignancies&#xD;
&#xD;
          -  Iron deficiency&#xD;
&#xD;
          -  Known positive test for human immunodeficiency virus infection&#xD;
&#xD;
          -  Received greater than 2 units of packed red blood cells within 4 weeks of&#xD;
             randomization or any RBC transfusions within 2 weeks before randomization&#xD;
&#xD;
          -  Received rHuEPO or darbepoetin alfa therapy within 4 weeks of randomization&#xD;
&#xD;
          -  Previous chemotherapy for SCLC&#xD;
&#xD;
          -  Previous radiotherapy except as symptom palliation for bone or brain lesions and at&#xD;
             least 24 hours since prior radiotherapy for symptom palliation providing extent of&#xD;
             radiotherapy makes marked bone marrow suppression unlikely&#xD;
&#xD;
          -  Less than 30 days since receipt of any drug or device that is not approved for any&#xD;
             indication&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Not using adequate contraceptive precautions&#xD;
&#xD;
          -  Previously randomized into this study&#xD;
&#xD;
          -  Known hypersensitivity to recombinant mammalian-derived product or any other&#xD;
             ingredients contained in the study drug&#xD;
&#xD;
          -  Any medical, mental, or other conditions that makes the subject unsuitable for&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://download.veritasmedicine.com/REGFILES/amgen/20010145_Clinical_Trial_Posting.pdf</url>
    <description>To access clinical trial results information click on this link</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf</url>
    <description>Notice regarding posted summaries of trial results</description>
  </link>
  <link>
    <url>http://download.veritasmedicine.com/REGFILES/amgen/20010145_Clinical_Trial_Posting_Apr_20.pdf</url>
    <description>To access clinical trial results information click on this link</description>
  </link>
  <results_reference>
    <citation>Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol. 2008 May 10;26(14):2342-9. doi: 10.1200/JCO.2007.15.0748.</citation>
    <PMID>18467726</PMID>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>July 7, 2005</study_first_submitted>
  <study_first_submitted_qc>July 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2005</study_first_posted>
  <last_update_submitted>August 7, 2008</last_update_submitted>
  <last_update_submitted_qc>August 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Oncology</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Darbepoetin alfa</keyword>
  <keyword>Survival</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Extensive Stage Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

